Context Therapeutics（CNTX）株式概要臨床段階のバイオ医薬品企業であるコンテクスト・セラピューティクス社は、固形がん治療薬の開発を行っている。 詳細CNTX ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( $0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない US市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るCNTX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$2.16該当なし内在価値ディスカウントEst. Revenue$PastFuture-40m162016201920222025202620282031Revenue US$16.4Earnings US$2.4AdvancedSet Fair ValueView all narrativesContext Therapeutics Inc. 競合他社Oramed PharmaceuticalsSymbol: NasdaqCM:ORMPMarket cap: US$187.7mMediWoundSymbol: NasdaqGM:MDWDMarket cap: US$210.9mMilestone PharmaceuticalsSymbol: NasdaqGS:MISTMarket cap: US$204.8mJourney MedicalSymbol: NasdaqCM:DERMMarket cap: US$174.3m価格と性能株価の高値、安値、推移の概要Context Therapeutics過去の株価現在の株価US$2.1652週高値US$3.6252週安値US$0.49ベータ1.571ヶ月の変化-11.11%3ヶ月変化-6.09%1年変化203.46%3年間の変化232.82%5年間の変化n/aIPOからの変化-57.65%最新ニュースお知らせ • Apr 02Context Therapeutics Announces Ctim-76 Receives Fda Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerContext Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate. The FDA’s Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on clinicaltrials.gov.お知らせ • Mar 17Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026.Price Target Changed • Dec 22Price target increased by 7.8% to US$5.57Up from US$5.17, the current price target is an average from 7 analysts. New target price is 364% above last closing price of US$1.20. Stock is up 22% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.46 last year.分析記事 • Dec 19We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Dec 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$95.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$95.6m market cap).New Risk • Nov 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).最新情報をもっと見るRecent updatesお知らせ • Apr 02Context Therapeutics Announces Ctim-76 Receives Fda Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerContext Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate. The FDA’s Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on clinicaltrials.gov.お知らせ • Mar 17Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026.Price Target Changed • Dec 22Price target increased by 7.8% to US$5.57Up from US$5.17, the current price target is an average from 7 analysts. New target price is 364% above last closing price of US$1.20. Stock is up 22% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.46 last year.分析記事 • Dec 19We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Dec 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$95.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$95.6m market cap).New Risk • Nov 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.4% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).お知らせ • Sep 03Nasdaq Grants Context Therapeutics Inc. an Additional 180 Calendar Days to Regain Compliance with Nasdaq Listing Rule 5550(a)(2)On August 28, 2025, Context Therapeutics Inc. (the Company") received written notice (the Extension Letter") from The Nasdaq Stock Market LLC (Nasdaq") informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the Extension Deadline"), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule"). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company's common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Rule because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Rule. These options include effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will regain compliance with the Minimum Bid Price Rule by the Extension Deadline.分析記事 • Aug 03Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...New Risk • Jun 26New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$45m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$58.7m market cap).Recent Insider Transactions • Jun 11Co-Founder recently bought US$70k worth of stockOn the 9th of June, Martin Lehr bought around 100k shares on-market at roughly US$0.70 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Martin's only on-market trade for the last 12 months.お知らせ • May 06Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025Context Therapeutics Inc. announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10, 2025. Dr. Smith will continue in a dual capacity as interim CMO and a member of the Company’s Board of Directors (“Board”) while the Company conducts a search for a new, full-time CMO. Dr. Smith has served on Context’s Board since 2024 and is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She was previously Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals and has also held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb.お知らせ • Apr 30Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual MeetingContext Therapeutics Inc. announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. Findings from preclinical studies evaluating CT-95 in cancer cell lines and tumor models illustrate the potential of CT-95 to treat mesothelin-positive tumors. Notably, CT-95 has shown to: Selectively bind to mesothelin-expressing cells and targets a unique, membrane-proximal region of mesothelin Avoid impact of shed mesothelin sink Be highly active and well tolerated across in vivo models Activate T cells without inducing broad cytokine release Findings from preclinical studies evaluating CT-95 in cancer cell lines and tumor models illustrate the potential of CT-95 to treat mesothelin-positive tumors. Notably, CT-95 has shown to: Selectively bind to mesothelin-expressing cells and targets a unique, membrane-proximal region of mesothelin Avoid impact of shed mesothelin sink Be highly active and well tolerated across in vivo models Activate T cells without inducing broad cytokine release. CT-95 is a mesothelin (“MSLN”) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. One challenge in developing MSLN-targeted therapies has been the presence of MSLN fragments, also referred to as shed MSLN, found in both blood and the tumor microenvironment that can serve as a decoy or sink for MSLN-targeting antibodies. CT-95 is a fully humanized bispecific T cell engager that has a moderate affinity but high avidity for membrane-bound MSLN, that is intended to minimize the impact of the shed MSLN. The clinical trial is being conducted at clinical sites in the US.Price Target Changed • Apr 29Price target decreased by 19% to US$5.75Down from US$7.08, the current price target is an average from 4 analysts. New target price is 553% above last closing price of US$0.88. Stock is down 35% over the past year. The company is forecast to post a net loss per share of US$0.28 next year compared to a net loss per share of US$0.46 last year.New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 5.5% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (462% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$52m net loss in 3 years). Market cap is less than US$100m (US$74.8m market cap).お知らせ • Apr 09Context Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of CT-95Context Therapeutics Inc. announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody designed to target mesothelin-expressing cancers. The Company anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026. This milestone marks Context's second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 ("CLDN6") x CD3 TCE bispecific antibody currently being evaluated in CLDN6-positive tumors, including ovarian, endometrial, and testicular cancers. MSLN is a membrane protein overexpressed in an estimated 30% of all cancers with limited expression in normal tissues. CTIM-95 is being developed as a therapy for advanced cancers associated with MSLN expression, including pancreatic, ovarian, mesothelioma, and other solid tumors. The Phase 1 clinical trial of CT -95 (NCT06756035) is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CT-95 in subjects with MSLN-expressing advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The dose escalation portion of the study is expected to enroll up to 30 patients.お知らせ • Apr 07Context Therapeutics Inc., Annual General Meeting, Jun 12, 2025Context Therapeutics Inc., Annual General Meeting, Jun 12, 2025.分析記事 • Mar 30We're Not Very Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Mar 01Context Therapeutics Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price RuleOn February 27, 2025, Context Therapeutics Inc. received written notice from The Nasdaq Stock Market LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until August 26, 2025, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). If at any time before that date the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the Minimum Bid Price Rule. If the Company does not regain compliance by August 26, 2025, the Company may be eligible for an additional 180-day grace period. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the minimum bid requirement. However, there can be no assurance that the Company will regain compliance with the minimum bid requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance, or maintain compliance with the other Nasdaq listing requirements.お知らせ • Jan 15Context Therapeutics Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76Context Therapeutics Inc. announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody. The Phase 1 dose escalation and expansion trial is enrolling patients with CLDN6-positive gynecologic and testicular cancers. The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The study is expected to enroll up to 70 patients. About CTIM-76: CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.お知らせ • Jan 13Context Therapeutics Inc. Announces Board ChangesContext Therapeutics Inc. announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025. Andy Pasternak is a biopharmaceutical executive and expert with over 25 years of experience, and currently serves as an Advisory Partner at Bain & Company, a leading global consulting firm. Most recently, Mr. Pasternak served as Executive Vice President, Chief Strategy Officer at Horizon Therapeutics, a biotechnology company focused on serious, rare autoimmune diseases; in this role, he was responsible for corporate strategy, M&A /business development, commercial development, and portfolio management, and he played a central role in the $28 billion acquisition of Horizon by Amgen Inc. in 2023. Prior to joining Horizon in 2019, Mr. Pasternak was a senior partner at Bain & Company, where he served as Head of the Healthcare Practice in the Americas. Mr. Pasternak currently serves on the Board of Directors of Endo Inc., a specialty pharmaceutical company. Mr. Pasternak is also an adjunct lecturer at the Kellogg School of Management at Northwestern University and member of the advisory board of the Healthcare at Kellogg Program.Price Target Changed • Jan 08Price target decreased by 7.1% to US$7.08Down from US$7.63, the current price target is an average from 6 analysts. New target price is 485% above last closing price of US$1.21. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$1.50 last year.New Risk • Dec 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (370% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$41m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$96.7m market cap).お知らせ • Dec 03Context Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Context Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Sep 04Context Therapeutics Appoints Karen Smith and Luke Walker to Board of DirectorsContext Therapeutics Inc. announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. Dr. Karen Smith is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She has been a key contributor to the successful development of multiple approved products in several therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox), neuroscience (Abilify) and anti-infectives (Teflaro). Previously, she was Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals. Earlier in her career, Dr. Smith held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. Previously, Dr. Smith served on the Board of Directors of Antares Pharma (acquired by Halozyme for $960 million), Acceleron Pharma (acquired by Merck for $11.5 billion), Mariana Oncology (acquired by Novartis for $1 billion upfront), and Sucampo Pharmaceuticals (acquired by Mallinckrodt for $1.2 billion). Dr. Smith currently serves on the Board of Directors of Aurinia Pharmaceuticals, Capstan Therapeutics, Sangamo Therapeutics, and Skye Bioscience. Dr. Luke Walkerhas more than 20 years of clinical development experience as both an executive and board member. Most recently, he was the Chief Medical Officer of Harpoon Therapeutics, an oncology-focused biopharmaceutical company where he was responsible for oversight of all aspects of clinical development programs using Harpoon’s TriTAC T-cell engager platform, which was acquired by Merck in 2024 for $680 million. Previously, Dr. Walker was Vice President of Clinical Development at Seagen, where he was the global development lead for Tukysa (tucatinib) through the program’s successful completion of a pivotal registrational trial and successful regulatory approvals. Earlier, Dr. Walker was Senior Vice President of Clinical Development at Cascadian Therapeutics, which was acquired by Seagen in 2018 for $614 million. Dr. Walker began his career as a practicing medical oncologist and hematologist at Providence Regional Medical Center and with the Everett Clinic. Dr. Walker currently serves on the Board of Directors of Zentalis Pharmaceuticals.Price Target Changed • Aug 19Price target increased by 17% to US$7.63Up from US$6.50, the current price target is an average from 4 analysts. New target price is 201% above last closing price of US$2.53. Stock is up 148% over the past year. The company is forecast to post a net loss per share of US$0.29 next year compared to a net loss per share of US$1.50 last year.分析記事 • Aug 15We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. By way of example, Context...お知らせ • Aug 02Context Therapeutics Inc. Appoints Claudio Dansky Ullmann as Chief Medical OfficerContext Therapeutics Inc. announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer (CMO). are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to team at this exciting time as the Company advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials, said Martin Lehr, CEO of Context. Dr. Dansky Ullmann and Ms. Andreas are industry veterans with deep expertise in oncology and T cell therapies, and a proven track record of advancing programs through clinical development. Dr. Dansky Ullmann brings over 30 years of experience in early and late-stage oncology therapeutics development. Most recently, he was the CMO at Avenge Bio, where Dr. Dansky Ullmann guided the clinical advancement of AVB-001 allogeneic cell therapy for ovarian cancer. Prior to Avenge, Dr. Dansky Ullmann was CMO at MaxCyte where he was responsible for the development of the CARMA chimeric antigen receptor (CAR) therapy program, including MCY-M11, a mesothelin-targeting CAR therapy. Previously, he was the Senior Vice President, Head of Clinical Development at Infinity Pharmaceuticals, where he led the development of Copiktra through FDA approval and eganelisib through first in human studies. Earlier, he was Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann was a Senior Investigator in the Cancer Therapy Evaluation Program at the National Cancer Institute, where he was involved in the strategic development of novel agents through Phase 1-3 clinical trials. Dr. Dansky Ullmann earned his M.D. at the School of Medicine, Universidad de Buenos Aires and completed his medical oncology training at Guemes Private Hospital, Buenos Aires.New Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 370% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (370% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$36m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change).Breakeven Date Change • May 12Forecast to breakeven in 2025The 3 analysts covering Context Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 22% to 2024. The company is expected to make a profit of US$2.16m in 2025.Price Target Changed • May 10Price target increased by 9.9% to US$3.70Up from US$3.37, the current price target is an average from 3 analysts. New target price is 98% above last closing price of US$1.87. Stock is up 236% over the past year. The company is forecast to post a net loss per share of US$1.36 next year compared to a net loss per share of US$1.50 last year.お知らせ • May 03+ 1 more updateContext Therapeutics Inc. announced that it expects to receive $99.992767 million in fundingContext Therapeutics Inc. announced that it has entered into a securities purchase agreement with the purchasers named therein to issue 59,032,259 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.55 per Share for the gross proceeds of $91,500,001.45 and pre-funded warrants to purchase 5,482,741 shares of Common Stock at a purchase price of $1.549 per Pre-Funded Warrant for the gross proceeds of $8,492,765.809 for the aggregate gross proceeds of $99,992,767.259 on May 1, 2024. The Pre-Funded Warrants will have an exercise price of $0.001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holder of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holder of Pre-Funded Warrants may increase or decrease such percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The aggregate gross proceeds for the Private Placement are expected to be approximately $100 million, before deducting offering expenses, and the Private Placement is expected to close on May 6, 2024, subject to customary closing conditions.お知らせ • Apr 28Context Therapeutics Inc., Annual General Meeting, Jun 13, 2024Context Therapeutics Inc., Annual General Meeting, Jun 13, 2024, at 08:30 US Eastern Standard Time. Agenda: To consider and ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; to consider and elect Richard Berman, Dr. Philip Kantoff, Martin Lehr, Jennifer Evans Stacey and Linda West to Board of Directors, each to serve until our 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified; and to consider and conduct any other business properly brought before the Annual Meeting.お知らせ • Apr 02Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersContext Therapeutics Inc. announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Chairman of the Board Richard Jay Berman was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Mar 27We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Mar 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$38m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$19.2m market cap).分析記事 • Sep 28Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Sep 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$14.4m market cap).Price Target Changed • Aug 13Price target decreased by 13% to US$2.10Down from US$2.42, the current price target is provided by 1 analyst. New target price is 83% above last closing price of US$1.15. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$1.30 next year compared to a net loss per share of US$0.93 last year.お知らせ • Jun 21Context Therapeutics Regains Compliance with Minimum Bid Price RuleOn June 15, 2023, Context Therapeutics Inc. (the ‘company’) received a letter (the ‘Compliance Letter’) from Nasdaq notifying the company that, for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater and that the company has regained compliance with the Minimum Bid Price Rule. Accordingly, Nasdaq considers the matter closed. As previously disclosed by the company on that certain Current Report on Form 8-K filed on January 27, 2023 with the U.S. Securities and Exchange Commission (the ‘SEC’), on January 24, 2023, the Company received written notice (the ‘Notification Letter’) from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’) because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter provided the Company an initial 180 calendar day period, or until July 24, 2023, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3) (A).分析記事 • Jun 05Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • Mar 26Price target decreased by 55% to US$2.24Down from US$4.94, the current price target is provided by 1 analyst. New target price is 261% above last closing price of US$0.62. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$0.65 next year compared to a net loss per share of US$0.93 last year.お知らせ • Feb 07Context Therapeutics Inc. Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerContext Therapeutics Inc. announced that two patients have achieved a confirmed partial response (PR) among the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context’s oral progesterone receptor antagonist onapristone extended release (ONA-XR) in combination with anastrozole (ANA) to treat hormone receptor positive (HR+) metastatic endometrial cancer (EC). Metastatic EC is an aggressive cancer of the uterus that is the fourth leading cause of cancer-related mortality in women and results in approximately 13,000 deaths per year in the United States. Current treatments are limited, with platinum plus taxane combination chemotherapy being the standard of care for first line metastatic disease. After first-line therapy, patients are typically treated with additional toxic infusion therapies, including chemotherapy or Lenvima® (lenvatinib) plus Keytruda® (pembrolizumab) combination therapy. Clinician and patient feedback indicates a high unmet need for a novel orally administered therapeutic that provides toxic therapy-like efficacy but with fewer debilitating side effects. Grade 3 or higher adverse events (AE) with standard EC therapies include diarrhea, nausea, vomiting, and hypertension. Preliminary data from the ongoing Phase 2 OATH clinical trial evaluating the combination of ONA-XR with ANA in HR+ EC found that ONA-XR plus ANA demonstrated a 4-month progression free survival (PFS) rate of 77% and an overall response rate (ORR) of 22%. These results suggest that ONA-XR plus ANA exhibits favorable efficacy and tolerability relative to historical data that evaluated physician’s choice of chemotherapy (doxorubicin or paclitaxel) versus Lenvima plus Keytruda combination therapy in a similar treatment setting of metastatic EC. Updated data regarding the Phase 2 OATH trial is expected to be provided in second quarter of 2023.お知らせ • Jan 06Context Therapeutics Inc. Enrolls the First Patient in the Elona StudyIn January 2023, Context Therapeutics Inc. enrolled the first patient in the ELONA study, an open-label, Phase 1b/2 breast cancer clinical trial being conducted in partnership with The Menarini Group ("Menarini”). The ELONA study is designed to explore the efficacy of ONA-XR in combination with elacestrant, Menarini’s selective estrogen receptor degrader, in patients with locally advanced or metastatic breast cancer who have received prior treatment with a CDK4/6 inhibitor. In Menarini’s recently completed EMERALD Phase 3 trial, elacestrant demonstrated a 0.9-month PFS improvement versus the standard-of-care fulvestrant (2.8 vs 1.9 months) in a similar treatment population and as a result may become the standard-of-care antiestrogen treatment2. Compared to elacestrant alone, Context believes that the combination of ONA-XR plus elacestrant may more completely inhibit progesterone and estrogen hormone signaling that is required for breast cancer growth and metastasis. Such a combination would potentially improve outcomes in patients without adding significant toxicity.Seeking Alpha • Sep 27Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24Context Therapeutics (NASDAQ:CNTX) on Tuesday updated cash guidance to extend its runway into Q1 2024. The company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures, and prioritize its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program. CNTX said it is evaluating ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients, who have previously been treated with a CDK4/6 inhibitor in Q4 this year and to report Phase 1b data in Q4 2023.分析記事 • Sep 15We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Aug 11Context Therapeutics GAAP EPS of -$0.25 in-lineContext Therapeutics press release (NASDAQ:CNTX): Q2 GAAP EPS of -$0.25 in-line. Cash, cash equivalents, and restricted cash were $42.9 million.Seeking Alpha • Aug 02Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trialContext Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.分析記事 • May 28Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Jan 01High number of new directorsIndependent Chairman of the Board Richard Berman was the last director to join the board, commencing their role in 2021.Seeking Alpha • Nov 02Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant PotentialContext Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications. Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of September of 2021. Context Therapeutics debuted last week at a far lower price than originally contemplated, while the sector (XBI) was almost 40% down from its February high. In my opinion, this company is undervalued and an opportunity exists to take a position before the larger market realizes the potential within Context's pipeline.株主還元CNTXUS PharmaceuticalsUS 市場7D-9.2%2.0%-0.3%1Y203.5%34.8%24.0%株主還元を見る業界別リターン: CNTX過去 1 年間で34.8 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: CNTX過去 1 年間で24 % の収益を上げたUS市場を上回りました。価格変動Is CNTX's price volatile compared to industry and market?CNTX volatilityCNTX Average Weekly Movement11.9%Pharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: CNTXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CNTXの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201515Martin Lehrwww.contexttherapeutics.com臨床段階のバイオ医薬品企業であるコンテクスト・セラピューティクス社は、固形癌の治療薬を開発している。同社の製品候補には、クローディン6（CLDN6）×CD3二重特異性抗体であるCTIM-76があり、CLDN6を発現する悪性細胞に対してT細胞を介した溶解をリダイレクトすることを目的としている。同社はIntegral Molecular, Inc.とがん治療用CLDN6二特異性モノクローナル抗体の開発に関する共同研究およびライセンス契約を締結している。同社は2015年に法人化され、ペンシルベニア州フィラデルフィアに本社を置いている。もっと見るContext Therapeutics Inc. 基礎のまとめContext Therapeutics の収益と売上を時価総額と比較するとどうか。CNTX 基礎統計学時価総額US$198.46m収益（TTM）-US$40.23m売上高(TTM)n/a0.0xP/Sレシオ-4.9xPER（株価収益率CNTX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CNTX 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$40.23m収益-US$40.23m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.44グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%CNTX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/17 03:28終値2026/05/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Context Therapeutics Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Li Wang WatsekCantor Fitzgerald & Co.Silvan TuerkcanCitizens JMP Securities, LLCJason KolbertD. Boral Capital LLC.8 その他のアナリストを表示
お知らせ • Apr 02Context Therapeutics Announces Ctim-76 Receives Fda Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerContext Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate. The FDA’s Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on clinicaltrials.gov.
お知らせ • Mar 17Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026.
Price Target Changed • Dec 22Price target increased by 7.8% to US$5.57Up from US$5.17, the current price target is an average from 7 analysts. New target price is 364% above last closing price of US$1.20. Stock is up 22% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.46 last year.
分析記事 • Dec 19We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Dec 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$95.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$95.6m market cap).
New Risk • Nov 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Apr 02Context Therapeutics Announces Ctim-76 Receives Fda Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerContext Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate. The FDA’s Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on clinicaltrials.gov.
お知らせ • Mar 17Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026Context Therapeutics Inc., Annual General Meeting, Jun 24, 2026.
Price Target Changed • Dec 22Price target increased by 7.8% to US$5.57Up from US$5.17, the current price target is an average from 7 analysts. New target price is 364% above last closing price of US$1.20. Stock is up 22% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.46 last year.
分析記事 • Dec 19We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Dec 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$95.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$95.6m market cap).
New Risk • Nov 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.4% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).
お知らせ • Sep 03Nasdaq Grants Context Therapeutics Inc. an Additional 180 Calendar Days to Regain Compliance with Nasdaq Listing Rule 5550(a)(2)On August 28, 2025, Context Therapeutics Inc. (the Company") received written notice (the Extension Letter") from The Nasdaq Stock Market LLC (Nasdaq") informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the Extension Deadline"), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Rule"). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company's common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Rule because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Rule. These options include effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will regain compliance with the Minimum Bid Price Rule by the Extension Deadline.
分析記事 • Aug 03Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
New Risk • Jun 26New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$45m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$58.7m market cap).
Recent Insider Transactions • Jun 11Co-Founder recently bought US$70k worth of stockOn the 9th of June, Martin Lehr bought around 100k shares on-market at roughly US$0.70 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Martin's only on-market trade for the last 12 months.
お知らせ • May 06Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025Context Therapeutics Inc. announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10, 2025. Dr. Smith will continue in a dual capacity as interim CMO and a member of the Company’s Board of Directors (“Board”) while the Company conducts a search for a new, full-time CMO. Dr. Smith has served on Context’s Board since 2024 and is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She was previously Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals and has also held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb.
お知らせ • Apr 30Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual MeetingContext Therapeutics Inc. announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. Findings from preclinical studies evaluating CT-95 in cancer cell lines and tumor models illustrate the potential of CT-95 to treat mesothelin-positive tumors. Notably, CT-95 has shown to: Selectively bind to mesothelin-expressing cells and targets a unique, membrane-proximal region of mesothelin Avoid impact of shed mesothelin sink Be highly active and well tolerated across in vivo models Activate T cells without inducing broad cytokine release Findings from preclinical studies evaluating CT-95 in cancer cell lines and tumor models illustrate the potential of CT-95 to treat mesothelin-positive tumors. Notably, CT-95 has shown to: Selectively bind to mesothelin-expressing cells and targets a unique, membrane-proximal region of mesothelin Avoid impact of shed mesothelin sink Be highly active and well tolerated across in vivo models Activate T cells without inducing broad cytokine release. CT-95 is a mesothelin (“MSLN”) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. One challenge in developing MSLN-targeted therapies has been the presence of MSLN fragments, also referred to as shed MSLN, found in both blood and the tumor microenvironment that can serve as a decoy or sink for MSLN-targeting antibodies. CT-95 is a fully humanized bispecific T cell engager that has a moderate affinity but high avidity for membrane-bound MSLN, that is intended to minimize the impact of the shed MSLN. The clinical trial is being conducted at clinical sites in the US.
Price Target Changed • Apr 29Price target decreased by 19% to US$5.75Down from US$7.08, the current price target is an average from 4 analysts. New target price is 553% above last closing price of US$0.88. Stock is down 35% over the past year. The company is forecast to post a net loss per share of US$0.28 next year compared to a net loss per share of US$0.46 last year.
New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 5.5% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (462% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$52m net loss in 3 years). Market cap is less than US$100m (US$74.8m market cap).
お知らせ • Apr 09Context Therapeutics Inc. Doses First Patient in Phase 1 Clinical Trial of CT-95Context Therapeutics Inc. announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody designed to target mesothelin-expressing cancers. The Company anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026. This milestone marks Context's second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 ("CLDN6") x CD3 TCE bispecific antibody currently being evaluated in CLDN6-positive tumors, including ovarian, endometrial, and testicular cancers. MSLN is a membrane protein overexpressed in an estimated 30% of all cancers with limited expression in normal tissues. CTIM-95 is being developed as a therapy for advanced cancers associated with MSLN expression, including pancreatic, ovarian, mesothelioma, and other solid tumors. The Phase 1 clinical trial of CT -95 (NCT06756035) is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CT-95 in subjects with MSLN-expressing advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The dose escalation portion of the study is expected to enroll up to 30 patients.
お知らせ • Apr 07Context Therapeutics Inc., Annual General Meeting, Jun 12, 2025Context Therapeutics Inc., Annual General Meeting, Jun 12, 2025.
分析記事 • Mar 30We're Not Very Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Mar 01Context Therapeutics Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price RuleOn February 27, 2025, Context Therapeutics Inc. received written notice from The Nasdaq Stock Market LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until August 26, 2025, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). If at any time before that date the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the Minimum Bid Price Rule. If the Company does not regain compliance by August 26, 2025, the Company may be eligible for an additional 180-day grace period. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the minimum bid requirement. However, there can be no assurance that the Company will regain compliance with the minimum bid requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance, or maintain compliance with the other Nasdaq listing requirements.
お知らせ • Jan 15Context Therapeutics Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76Context Therapeutics Inc. announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody. The Phase 1 dose escalation and expansion trial is enrolling patients with CLDN6-positive gynecologic and testicular cancers. The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The study is expected to enroll up to 70 patients. About CTIM-76: CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.
お知らせ • Jan 13Context Therapeutics Inc. Announces Board ChangesContext Therapeutics Inc. announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who stepped down from the Board effective January 12, 2025. Andy Pasternak is a biopharmaceutical executive and expert with over 25 years of experience, and currently serves as an Advisory Partner at Bain & Company, a leading global consulting firm. Most recently, Mr. Pasternak served as Executive Vice President, Chief Strategy Officer at Horizon Therapeutics, a biotechnology company focused on serious, rare autoimmune diseases; in this role, he was responsible for corporate strategy, M&A /business development, commercial development, and portfolio management, and he played a central role in the $28 billion acquisition of Horizon by Amgen Inc. in 2023. Prior to joining Horizon in 2019, Mr. Pasternak was a senior partner at Bain & Company, where he served as Head of the Healthcare Practice in the Americas. Mr. Pasternak currently serves on the Board of Directors of Endo Inc., a specialty pharmaceutical company. Mr. Pasternak is also an adjunct lecturer at the Kellogg School of Management at Northwestern University and member of the advisory board of the Healthcare at Kellogg Program.
Price Target Changed • Jan 08Price target decreased by 7.1% to US$7.08Down from US$7.63, the current price target is an average from 6 analysts. New target price is 485% above last closing price of US$1.21. The company is forecast to post a net loss per share of US$0.58 next year compared to a net loss per share of US$1.50 last year.
New Risk • Dec 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (370% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$41m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$96.7m market cap).
お知らせ • Dec 03Context Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Context Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Sep 04Context Therapeutics Appoints Karen Smith and Luke Walker to Board of DirectorsContext Therapeutics Inc. announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors. Dr. Karen Smith is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She has been a key contributor to the successful development of multiple approved products in several therapeutic areas, including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox), neuroscience (Abilify) and anti-infectives (Teflaro). Previously, she was Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals. Earlier in her career, Dr. Smith held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. Previously, Dr. Smith served on the Board of Directors of Antares Pharma (acquired by Halozyme for $960 million), Acceleron Pharma (acquired by Merck for $11.5 billion), Mariana Oncology (acquired by Novartis for $1 billion upfront), and Sucampo Pharmaceuticals (acquired by Mallinckrodt for $1.2 billion). Dr. Smith currently serves on the Board of Directors of Aurinia Pharmaceuticals, Capstan Therapeutics, Sangamo Therapeutics, and Skye Bioscience. Dr. Luke Walkerhas more than 20 years of clinical development experience as both an executive and board member. Most recently, he was the Chief Medical Officer of Harpoon Therapeutics, an oncology-focused biopharmaceutical company where he was responsible for oversight of all aspects of clinical development programs using Harpoon’s TriTAC T-cell engager platform, which was acquired by Merck in 2024 for $680 million. Previously, Dr. Walker was Vice President of Clinical Development at Seagen, where he was the global development lead for Tukysa (tucatinib) through the program’s successful completion of a pivotal registrational trial and successful regulatory approvals. Earlier, Dr. Walker was Senior Vice President of Clinical Development at Cascadian Therapeutics, which was acquired by Seagen in 2018 for $614 million. Dr. Walker began his career as a practicing medical oncologist and hematologist at Providence Regional Medical Center and with the Everett Clinic. Dr. Walker currently serves on the Board of Directors of Zentalis Pharmaceuticals.
Price Target Changed • Aug 19Price target increased by 17% to US$7.63Up from US$6.50, the current price target is an average from 4 analysts. New target price is 201% above last closing price of US$2.53. Stock is up 148% over the past year. The company is forecast to post a net loss per share of US$0.29 next year compared to a net loss per share of US$1.50 last year.
分析記事 • Aug 15We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. By way of example, Context...
お知らせ • Aug 02Context Therapeutics Inc. Appoints Claudio Dansky Ullmann as Chief Medical OfficerContext Therapeutics Inc. announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer (CMO). are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to team at this exciting time as the Company advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials, said Martin Lehr, CEO of Context. Dr. Dansky Ullmann and Ms. Andreas are industry veterans with deep expertise in oncology and T cell therapies, and a proven track record of advancing programs through clinical development. Dr. Dansky Ullmann brings over 30 years of experience in early and late-stage oncology therapeutics development. Most recently, he was the CMO at Avenge Bio, where Dr. Dansky Ullmann guided the clinical advancement of AVB-001 allogeneic cell therapy for ovarian cancer. Prior to Avenge, Dr. Dansky Ullmann was CMO at MaxCyte where he was responsible for the development of the CARMA chimeric antigen receptor (CAR) therapy program, including MCY-M11, a mesothelin-targeting CAR therapy. Previously, he was the Senior Vice President, Head of Clinical Development at Infinity Pharmaceuticals, where he led the development of Copiktra through FDA approval and eganelisib through first in human studies. Earlier, he was Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann was a Senior Investigator in the Cancer Therapy Evaluation Program at the National Cancer Institute, where he was involved in the strategic development of novel agents through Phase 1-3 clinical trials. Dr. Dansky Ullmann earned his M.D. at the School of Medicine, Universidad de Buenos Aires and completed his medical oncology training at Guemes Private Hospital, Buenos Aires.
New Risk • May 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 370% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (370% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$36m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change).
Breakeven Date Change • May 12Forecast to breakeven in 2025The 3 analysts covering Context Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 22% to 2024. The company is expected to make a profit of US$2.16m in 2025.
Price Target Changed • May 10Price target increased by 9.9% to US$3.70Up from US$3.37, the current price target is an average from 3 analysts. New target price is 98% above last closing price of US$1.87. Stock is up 236% over the past year. The company is forecast to post a net loss per share of US$1.36 next year compared to a net loss per share of US$1.50 last year.
お知らせ • May 03+ 1 more updateContext Therapeutics Inc. announced that it expects to receive $99.992767 million in fundingContext Therapeutics Inc. announced that it has entered into a securities purchase agreement with the purchasers named therein to issue 59,032,259 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.55 per Share for the gross proceeds of $91,500,001.45 and pre-funded warrants to purchase 5,482,741 shares of Common Stock at a purchase price of $1.549 per Pre-Funded Warrant for the gross proceeds of $8,492,765.809 for the aggregate gross proceeds of $99,992,767.259 on May 1, 2024. The Pre-Funded Warrants will have an exercise price of $0.001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holder of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holder of Pre-Funded Warrants may increase or decrease such percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. The aggregate gross proceeds for the Private Placement are expected to be approximately $100 million, before deducting offering expenses, and the Private Placement is expected to close on May 6, 2024, subject to customary closing conditions.
お知らせ • Apr 28Context Therapeutics Inc., Annual General Meeting, Jun 13, 2024Context Therapeutics Inc., Annual General Meeting, Jun 13, 2024, at 08:30 US Eastern Standard Time. Agenda: To consider and ratify the selection by the Audit Committee of the Board of Directors of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; to consider and elect Richard Berman, Dr. Philip Kantoff, Martin Lehr, Jennifer Evans Stacey and Linda West to Board of Directors, each to serve until our 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified; and to consider and conduct any other business properly brought before the Annual Meeting.
お知らせ • Apr 02Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersContext Therapeutics Inc. announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers. CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Chairman of the Board Richard Jay Berman was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Mar 27We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Mar 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$38m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$19.2m market cap).
分析記事 • Sep 28Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Sep 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$14.4m market cap).
Price Target Changed • Aug 13Price target decreased by 13% to US$2.10Down from US$2.42, the current price target is provided by 1 analyst. New target price is 83% above last closing price of US$1.15. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$1.30 next year compared to a net loss per share of US$0.93 last year.
お知らせ • Jun 21Context Therapeutics Regains Compliance with Minimum Bid Price RuleOn June 15, 2023, Context Therapeutics Inc. (the ‘company’) received a letter (the ‘Compliance Letter’) from Nasdaq notifying the company that, for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater and that the company has regained compliance with the Minimum Bid Price Rule. Accordingly, Nasdaq considers the matter closed. As previously disclosed by the company on that certain Current Report on Form 8-K filed on January 27, 2023 with the U.S. Securities and Exchange Commission (the ‘SEC’), on January 24, 2023, the Company received written notice (the ‘Notification Letter’) from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’) because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter provided the Company an initial 180 calendar day period, or until July 24, 2023, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3) (A).
分析記事 • Jun 05Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • Mar 26Price target decreased by 55% to US$2.24Down from US$4.94, the current price target is provided by 1 analyst. New target price is 261% above last closing price of US$0.62. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$0.65 next year compared to a net loss per share of US$0.93 last year.
お知らせ • Feb 07Context Therapeutics Inc. Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerContext Therapeutics Inc. announced that two patients have achieved a confirmed partial response (PR) among the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context’s oral progesterone receptor antagonist onapristone extended release (ONA-XR) in combination with anastrozole (ANA) to treat hormone receptor positive (HR+) metastatic endometrial cancer (EC). Metastatic EC is an aggressive cancer of the uterus that is the fourth leading cause of cancer-related mortality in women and results in approximately 13,000 deaths per year in the United States. Current treatments are limited, with platinum plus taxane combination chemotherapy being the standard of care for first line metastatic disease. After first-line therapy, patients are typically treated with additional toxic infusion therapies, including chemotherapy or Lenvima® (lenvatinib) plus Keytruda® (pembrolizumab) combination therapy. Clinician and patient feedback indicates a high unmet need for a novel orally administered therapeutic that provides toxic therapy-like efficacy but with fewer debilitating side effects. Grade 3 or higher adverse events (AE) with standard EC therapies include diarrhea, nausea, vomiting, and hypertension. Preliminary data from the ongoing Phase 2 OATH clinical trial evaluating the combination of ONA-XR with ANA in HR+ EC found that ONA-XR plus ANA demonstrated a 4-month progression free survival (PFS) rate of 77% and an overall response rate (ORR) of 22%. These results suggest that ONA-XR plus ANA exhibits favorable efficacy and tolerability relative to historical data that evaluated physician’s choice of chemotherapy (doxorubicin or paclitaxel) versus Lenvima plus Keytruda combination therapy in a similar treatment setting of metastatic EC. Updated data regarding the Phase 2 OATH trial is expected to be provided in second quarter of 2023.
お知らせ • Jan 06Context Therapeutics Inc. Enrolls the First Patient in the Elona StudyIn January 2023, Context Therapeutics Inc. enrolled the first patient in the ELONA study, an open-label, Phase 1b/2 breast cancer clinical trial being conducted in partnership with The Menarini Group ("Menarini”). The ELONA study is designed to explore the efficacy of ONA-XR in combination with elacestrant, Menarini’s selective estrogen receptor degrader, in patients with locally advanced or metastatic breast cancer who have received prior treatment with a CDK4/6 inhibitor. In Menarini’s recently completed EMERALD Phase 3 trial, elacestrant demonstrated a 0.9-month PFS improvement versus the standard-of-care fulvestrant (2.8 vs 1.9 months) in a similar treatment population and as a result may become the standard-of-care antiestrogen treatment2. Compared to elacestrant alone, Context believes that the combination of ONA-XR plus elacestrant may more completely inhibit progesterone and estrogen hormone signaling that is required for breast cancer growth and metastasis. Such a combination would potentially improve outcomes in patients without adding significant toxicity.
Seeking Alpha • Sep 27Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24Context Therapeutics (NASDAQ:CNTX) on Tuesday updated cash guidance to extend its runway into Q1 2024. The company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures, and prioritize its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program. CNTX said it is evaluating ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients, who have previously been treated with a CDK4/6 inhibitor in Q4 this year and to report Phase 1b data in Q4 2023.
分析記事 • Sep 15We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 11Context Therapeutics GAAP EPS of -$0.25 in-lineContext Therapeutics press release (NASDAQ:CNTX): Q2 GAAP EPS of -$0.25 in-line. Cash, cash equivalents, and restricted cash were $42.9 million.
Seeking Alpha • Aug 02Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trialContext Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.
分析記事 • May 28Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Jan 01High number of new directorsIndependent Chairman of the Board Richard Berman was the last director to join the board, commencing their role in 2021.
Seeking Alpha • Nov 02Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant PotentialContext Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications. Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of September of 2021. Context Therapeutics debuted last week at a far lower price than originally contemplated, while the sector (XBI) was almost 40% down from its February high. In my opinion, this company is undervalued and an opportunity exists to take a position before the larger market realizes the potential within Context's pipeline.
